We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

110 hedge funds and large institutions have $236M invested in CytomX Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 44 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.75% more ownership

Funds ownership: 82.85% → 83.6% (+0.75%)

4% less funds holding

Funds holding: 114 → 110 (-4)

14% less capital invested

Capital invested by funds: $275M → $236M (-$38.4M)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

17% less call options, than puts

Call options by funds: $238K | Put options by funds: $287K

39% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 44

Holders
110
Holders Change
-4
Holders Change %
-3.51%
% of All Funds
1.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
27
Reduced
44
Closed
25
Calls
$238K
Puts
$287K
Net Calls
-$49K
Net Calls Change
+$164K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$34M
2
RI
RTW Investments
New York
+$27.1M
3
RCMNY
Rubric Capital Management (New York)
New York
+$14.1M
4
O
OrbiMed
New York
+$8.16M
5
Millennium Management
Millennium Management
New York
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$17.8M
2
Victory Capital Management
Victory Capital Management
Texas
-$16.6M
3
CS
Candriam SCA
Luxembourg
-$9.05M
4
GPP
Great Point Partners
Connecticut
-$7.63M
5
State Street
State Street
Massachusetts
-$7.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.23M -$140K -23,936 -11%
Axa
27
Axa
France
$1.09M +$113K +19,300 +8%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$923K +$17.6K +2,998 +1%
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$874K +$860K +146,813 +267%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$873K +$2.34K +400 +0.2%
Two Sigma Investments
31
Two Sigma Investments
New York
$801K +$487K +83,111 +82%
Charles Schwab
32
Charles Schwab
California
$711K -$1.43K -244 -0.1%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$660K -$34.8K -5,932 -4%
TCM
34
Tang Capital Management
California
$660K +$892K +152,345 New
CC
35
Clearline Capital
New York
$628K +$849K +145,000 New
HF
36
HRT Financial
New York
$624K -$29.4K -5,016 -3%
UBS Group
37
UBS Group
Switzerland
$608K -$97.8K -16,692 -11%
PP
38
PDT Partners
New York
$585K +$172K +29,315 +28%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$567K -$207K -35,359 -21%
Citigroup
40
Citigroup
New York
$566K +$125K +21,300 +19%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$549K +$29.4K +5,017 +4%
AGA
42
Altrinsic Global Advisors
Connecticut
$520K – – –
PAM
43
Panagora Asset Management
Massachusetts
$489K +$685 +117 +0.1%
ECM
44
ExodusPoint Capital Management
New York
$465K +$409K +69,873 +186%
SO
45
STRS Ohio
Ohio
$462K – – –
Wells Fargo
46
Wells Fargo
California
$452K +$82.3K +14,055 +16%
PVI
47
Pura Vida Investments
New York
$420K -$14.4K -2,466 -2%
Allspring Global Investments
48
Allspring Global Investments
North Carolina
$393K +$532K +90,846 New
Morgan Stanley
49
Morgan Stanley
New York
$376K -$182K -30,989 -26%
PAG
50
Private Advisor Group
New Jersey
$365K -$235K -40,177 -32%
1
2
3 4 5

CTMX Hedge Fund Activity: Q4 2021 in Review

110 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2021, worth a combined $236M — down 14% from $275M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CTMX and 21 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 27 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $34M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.8M sold.

  • 110 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2021, down from 114 in Q3 2021.
  • Funds reported $236M of CytomX Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
  • 21 funds opened new CytomX Therapeutics positions in Q4 2021 and 25 closed out, a net change of -4 holders.
  • The largest CytomX Therapeutics buyer in Q4 2021 was BVF Inc, an estimated $34M added.
  • The largest CytomX Therapeutics seller in Q4 2021 was RA Capital Management, an estimated $17.8M sold.

Based on aggregated 13F filings for Q4 2021.